Check out the companies making news after the market closes. Lattice Semiconductor, Vertex Pharmaceuticals, Astera Labs, Coty, and CoreCivic saw significant movements in their stock prices.
Lattice Semiconductor saw its shares climb approximately 12% in extended trading after the chipmaker exceeded analysts' revenue projections for the fourth quarter. The company reported revenue of $117.4 million, surpassing the anticipated $117.1 million, according to LSEG. Vertex Pharmaceuticals experienced a slight dip of 1% in its stock price following mixed fourth-quarter results. While Vertex reported adjusted earnings of $3.98 per share, falling short of the expected $4.
03 per share, according to LSEG, its revenue of $2.91 billion exceeded forecasts of $2.78 billion. Astera Labs witnessed a nearly 2% increase in its share price after both its top and bottom lines exceeded expectations for the fourth quarter. The semiconductor company reported adjusted earnings of 37 cents on revenue of $141 million. Analysts polled by LSEG had projected earnings of 26 cents and revenue of $128 million. Notably, Astera Labs also provided first-quarter guidance that surpassed estimates. Coty, the beauty products manufacturer, faced a 2% decline in its stock value following the release of its fiscal second-quarter results, which fell short of Wall Street's anticipations. Coty reported adjusted earnings of 11 cents per share, below the 21 cents per share projected by analysts polled by LSEG. Revenue reached $1.67 billion, missing the consensus estimate of $1.72 billion. Management highlighted that foreign-exchange headwinds are anticipated to negatively impact the company's reported sales in the latter half of 2025. CoreCivic, the owner of private prisons, experienced a 4% decline in its stock price. The company projected full-year earnings to range between 48 cents and 61 cents per share, while analysts had predicted 82 cents per share, according to LSEG. However, CoreCivic's adjusted earnings and revenue for the fourth quarter surpassed expectations, reaching 16 cents per share and $479 million, respectively
STOCK MARKET EXTENDED TRADING CHIPMAKERS BIOTECHNOLOGY BEAUTY PRODUCTS
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Approves Vertex Pharmaceuticals' Non-Opioid Painkiller JournavxThe Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals' non-opioid painkiller, Journavx, marking a significant step forward in safer pain management. This milestone comes after years of efforts to develop alternatives to addictive opioids. Journavx works by blocking pain signals at their source, unlike opioids which directly impact the brain.
Read more »
Lattice Semiconductor Leads After Beating Q4 Revenue EstimatesCheck out the companies making headlines in extended trading: Lattice Semiconductor shares soared around 12% after the chipmaker beat analysts' expectations on revenue in the fourth quarter. Vertex Pharmaceuticals — The biotechnology stock slipped 1% on mixed fourth-quarter results. Astera Labs — Shares of the semiconductor company added nearly 2% after its top- and bottom-line beats in the fourth quarter.
Read more »
New Pain Drug Offers Hope but Faces Challenges: Vertex's Approach Breaks from OpioidsVertex Pharmaceuticals introduces a novel pain medication that targets pain signals before they reach the brain, offering a potential alternative to opioids. While clinical trials demonstrate modest effectiveness, experts commend its unique mechanism of action and reduced risk of addiction. The high cost of the drug, however, raises concerns about accessibility. Vertex remains focused on expanding its pain management pipeline despite recent setbacks.
Read more »
Vertex's New Non-Opioid Pain Drug Journavx Gets FDA ApprovalVertex Pharmaceuticals' non-opioid pain medication, suzetrigine (Journavx), has received FDA approval for treating moderate to severe acute pain in adults. This groundbreaking drug offers a promising alternative to opioids, targeting a pain-signaling pathway in the peripheral nervous system.
Read more »
FDA Approves Vertex's Non-Opioid Painkiller: A New Era in Pain ManagementThe Food and Drug Administration (FDA) has greenlit Vertex Pharmaceutical's non-opioid painkiller, presenting a groundbreaking alternative to traditional opioid-based pain relief options and offering hope in the fight against the opioid epidemic.
Read more »
FDA Approves Vertex's Non-Opioid Painkiller Journavx, Offering Hope for Millions Suffering from PainVertex Pharmaceuticals' non-opioid painkiller, Journavx, receives FDA approval, marking a significant milestone in the fight against the opioid epidemic. The drug offers a safe and effective alternative for pain relief without the risk of addiction.
Read more »